Skip to content

Although we don’t plan for a specific theme in any given quarter, sometimes a unifying concept emerges. This quarter, our list of innovations features examples where technology and biology inform and challenge each other to drive innovation forward. In one case, a machine learns to “listen” for power outages. In another, a quirk in the anatomy of the tongue is exploited to make food taste better through electrical signals. This list provides further evidence that multiple, concurrent technological advances across disciplines are building on each other, spurring a golden age of innovation.

New sensors “listen” to the grid to find power outages

A company has developed a sensor which is mounted on an electrical pole just below a powerline to listen to its sounds and vibrations. The sensor then uses artificial intelligence and signal processing software to “hear” the sounds and identify disturbances in the grid.

Why it matters: Utility companies currently spend hundreds of millions of dollars a year manually traversing lines to find outages. This method is time-intensive and carries a high risk of electrocution. Because an actual electrical grid is more like a guitar than a circuit board, linemen today “listen” to the grid to stay safe and locate issues. That technique inspired this new technology, which relies on a form of “hearing” to find and diagnose problems quickly and effectively.

Spoon uses electricity to mimic the taste of salt in food

Researchers out of Japan have invented a way for people to enjoy salt in food and its associated flavor enhancement without detracting from their health. Their solution is a spoon that can send a weak electrical current to the tongue, tricking the brain into thinking the food is saltier than it is.1 The current spoon design has four different intensity levels to let users decide how much salty flavor they want.

Why it matters: Currently, half a billion people worldwide have heart disease, and 1.3 billion people have hypertension. A high-salt diet can increase blood pressure, which can lead to heart disease and risk of early death. Because food tends to taste better when it is saltier, this innovation could have a material impact on global health without taking away flavor, one of many people’s joys in life.

Exhibit 1: AI Sound Sensor

A new sensor uses artificial intelligence to “hear” sounds that identify disturbances in the power grid, helping utility companies efficiently locate outages.

For illustrative purposes only.

Alternative to needles is invented

A team of medical scientists have now found a way to deliver vaccines, insulin and other medicines to patients without a needle. The device makes use of laser-induced cavitation, a process where a laser heats up a liquid until it forms a bubble and then bursts, creating a very small but powerful stream, known as a microfluidic jet.2 This jet replaces a conventional injection with a needle.

Why it matters: The US Centers for Disease Control and Prevention estimates that between two-thirds of children and one-quarter of adults have a strong fear of needles, which delays hundreds of millions of injections each year. Further, 32 billion single-use needles and syringes are used each year. This reusable device would eliminate unnecessary waste and deliver people the vaccines and other medicines they need.  

Knit sleeve simulates touch

A team from Stanford recently designed a knit sleeve that uses pressure to simulate touch and is also lightweight, wearable, and comfortable.3 The sleeve uses a battery-powered system of small, inflatable pouches that can fill rapidly with air. A knit sleeve provides flexibility, which is key to user comfort and function. The textile can be soft in some areas, like at the elbow, but stiff in other areas, where the pressure pouches need to act against the skin.

Why it matters: This invention signals potential for a new category of haptic devices. Prior similar devices used vibration instead of pressure and usually required users to wear stiff exoskeletons or other bulky structures. A survey of 32 users found that the pressure-based system felt more realistic. In the future, this technology will have applications in virtual reality, rehabilitation and silent communication.

AI that can design new genetic codes 

The Arc Institute, a non-profit collaboration with NVIDIA and leading universities, recently released an artificial intelligence model called Evo 2 trained on the DNA of over 100,000 species, including humans, plants, bacteria and fungi. The model has a deep understanding of the biological code, which means it can identify patterns in gene sequences across the tree of life that would take years for researchers to uncover on their own. Trained on over 9.3 trillion nucleotides, or 128,000 whole genomes, this is the largest model built for biology to date.4

Why it matters: Evo 2 can identify, at a much faster rate, disease-causing mutations in humans. For instance, when the model worked to predict the chance of breast cancer from the associated gene, BRCA1, it achieved over 90% accuracy. The model is even capable of creating new life forms by designing genomes.



IMPORTANT LEGAL INFORMATION

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. This material may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market. There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not necessarily indicative nor a guarantee of future performance. All investments involve risks, including possible loss of principal.

Any research and analysis contained in this material has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Data from third party sources may have been used in the preparation of this material and Franklin Templeton ("FT") has not independently verified, validated or audited such data.  Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase, hold or sell any securities, and the information provided regarding such individual securities (if any) is not a sufficient basis upon which to make an investment decision. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.

Franklin Templeton has environmental, social and governance (ESG) capabilities; however, not all strategies or products for a strategy consider “ESG” as part of their investment process.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued in the U.S. by Franklin Templeton, One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com. Investments are not FDIC insured; may lose value; and are not bank guaranteed.

You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.